Gilead extends Nurix deal. Gilead Sciences stock sits 2.76 percent below its high
Published on 10/14/2026 at 11:50 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWSPipeline and earnings calendar
- On October 5, 2026, Gilead extended its Nurix collaboration for two years.
- Second-quarter revenue reached USD 7.80 billion, up 10.60 percent year over year.
- Gilead Sciences stock trades at EUR 132.48 at 11:46 a.m. CEST at Lang & Schwarz on October 14, 2026, 0.32 percent below the Xetra close of October 13, 2026.
Gilead Sciences (ISIN US3755581036) was trading at EUR 132.48 at Lang & Schwarz on October 14, 2026, 2.76 percent below its EUR 136.24 52-week high. As Yahoo Finance reported on October 13, 2026, Gilead had announced a second two-year extension of its research collaboration with Nurix Therapeutics for an undisclosed oncology program.
Three dated pipeline developments
On September 15, 2026, Gilead announced an agreement with the Pan American Health Organization covering access to twice-yearly lenacapavir across 14 countries. The company then expanded voluntary licensing agreements on September 16, 2026, covering 120 high-incidence countries, according to Gilead Sciences.
The latest dated step came on October 5, 2026, when the Nurix research collaboration received a second two-year extension. The program has advanced GS-6791, an oral IRAK4 degrader, into Phase 1 development, giving the oncology pipeline a measurable clinical milestone.
What does the pipeline deal add
The commercial picture remains stronger than the headline earnings line. In the second quarter of 2026, revenue reached USD 7.80 billion, up 10.60 percent year over year, while the reported result included a diluted loss of USD 6.75 per share, according to MarketBeat on October 13, 2026. The revenue growth and the loss therefore point in different directions for investors assessing the pipeline.
Markets Insider reported on October 7, 2026, that JPMorgan raised its Gilead price target from USD 160.00 to USD 170.00 and maintained an Overweight rating. The same report said the bank expected another strong quarter for the HIV franchise, while Truist separately raised its target from USD 150.00 to USD 158.00 and kept a Buy rating.
Earnings date set for October 22
The next explicitly listed reporting date is October 22, 2026, for third-quarter results, according to The Wall Street Journal. Its estimate table shows consensus earnings per share of USD 2.15 for the third quarter, giving the upcoming release a clear numerical benchmark.
Stock stays below its yearly high
At 11:46 a.m. CEST on October 14, 2026, Gilead Sciences stock was trading at EUR 132.48 at Lang & Schwarz, 0.32 percent below the Xetra close of October 13, 2026 at EUR 132.90. The EUR 98.96 to EUR 136.24 52-week range places the quote 2.76 percent below its high, while the company carries a USD 183.4 billion market capitalization as of October 14, 2026.
The further course of trading is shown by the continuously updated real-time quote of Gilead Sciences stock.
Gilead Sciences market facts
- Company: Gilead Sciences, Inc.
- ISIN: US3755581036
- Ticker: GILD
- Primary exchange: NASDAQ
- Price Lang & Schwarz (as of October 14, 2026, 11:46 a.m. CEST): EUR 132.48
- Change versus Xetra close: minus 0.32 percent
- Xetra close (October 13, 2026): EUR 132.90
- Market capitalization: USD 183.4 billion (as of October 14, 2026)
- 52-week range: EUR 98.96-EUR 136.24 (as of October 14, 2026)
- Sector / Industry: Health Care / Pharmaceuticals
Market context: Market report S&P 500.
